Happy Authors

Recently Published Articles
  • 2020, June

    case report

    A Rare Case of Giant Cell MyocarditisOpen Access

    PDF662.00 KB 662.00 KB
    Full-Text (HTML)
    Abstract [+]

    Giant cell myocarditis is a rare condition first described in 1905. It has a reported incidence range from 0.007% to 0.051%. It affects female and male individuals, equally, and usually occurs in young and middle-aged persons. The underlying aetiology of giant cell myocarditis is unknown but it is thought to be mediated by T-lymphocytes. Diagnosis is made via histological examination of myocardial tissue and is characterized by a mixed inflammatory cell infiltrate with multinucleated giant cells and cardiomyocyte necrosis, predominantly affecting the ventricles. The following report describes a rare case of giant cell myocarditis in a 71-year-old man with a history of hypertension and heart failure, who died while waiting to be seen in the emergency department. Autopsy findings revealed an enlarged, dilated heart with histologic features in keeping with giant cell myocarditis, along with features of heart failure. Diagnosis of giant cell myocarditis is less common in the elderly age group, possibly due to a less severe disease process in this age group and it may be misdiagnosed because older individuals may have other cardiovascular diseases (CVDs).


    Myocarditis; Giant cell myocarditis; Autopsy; Elderly, Cardiovascular.

  • 2020, March

    case report

    Advanced Heart Failure Exacerbated by Discreet Left Ventricular Lead Non-CaptureOpen Access

    PDF698.54 KB 698.54 KB
    Full-Text (HTML)
    Abstract [+]

    This case report illustrates a challenging case of worsening heart failure in a previously well-compensated patient with unclear etiology. Further workup revealed the patient’s cardiac resynchronization therapy-defibrillator (CRT-D) left ventricle (LV) lead was losing capture during positional changes. This case demonstrates the importance of device optimization, as well as electrocardiogram (ECG) monitoring to elucidate possible causes of acute systolic heart failure.


    Cardiac resynchronization; cardiac resynchronization therapy (CRT); Systolic heart failure; Lead positioning;
    Advanced heart failure.

  • 2019, October


    Pulmonary Artery Hypertension in Children Living with Sickle Cell AnaemiaOpen Access

    PDF328.61 KB 328.61 KB
    Full-Text (HTML)
    Abstract [+]

    Pulmonary artery hypertension (PAH) ultimately leads to straining of the right ventricle and increases the risk of heart failure in affected patients. Its clinical presentation is similar to that of many other diseases thus delaying the diagnosis until the disease is far advanced. It remains one of the leading causes of death in adults with sickle cell anaemia (SCA) worldwide. It confers a high risk of death with two-year mortality rates as high as 40-50% even at modest elevation of pulmonary artery pressure. Median survival age after detection of the disease is said to be 25.6-months. Early detection of elevated pulmonary artery pressure in childhood and appropriate intervention by optimization of anti-haemolytic therapy may prevent the progression of this complication. The current writes up is a review of literatures on pulmonary artery hypertension among children with sickle cell anaemia. This will give information which will aid early diagnosis and treatment of pulmonary artery hypertension among children with sickle cell anaemia. This will ultimately improve the quality of life of children with sickle cell anaemia and reduce morbidity and mortality from the disease in adults and children living with sickle cell anaemia.


    Sickle cell anaemia; Pulmonary artery hypertension; Children.

About the Journal

Heart Research – Open Journal (HROJ) exclusively deals with the health of the heart and its disorders.

The HROJ aims to provide an open forum to bring healthcare professionals and researchers from clinical, translational and basic science communities together for dissemination and discussion of all things heart-related.

Progress in understanding how the heart works at every level (from molecules to cells to physiology) has already made a significant impact on how heart disease and failure is treated in the clinic, but its disorders still remain one of the leading causes of death and ill-health worldwide. Understanding and increasing awareness of the basic mechanism of heart disease and repair, clinical implications and disease management lies at the core of our journal, and we welcome a broad scope of submissions in these areas.

Aims and Scope

Heart Research – Open Journal (HROJ) is dedicated to the open dissemination and robust discussion in the area of cardiology and its related fields.

HROJ covers a wide array of subjects as given below

  • Acute rheumatic carditis
  • Heart transplantation
  • Angina pectoris
  • Coronary heart diseases (CHD)
  • Arrhythmias
  • Phlebitis
  • Atherosclerosis
  • 3D medical imaging and processing
  • Clinical cardiovascular pharmacology
  • Permanent pacemaker implantation
  • Coronary stenting
  • Congestive heart failure

Submissions for this Journal are accepted from the very basic cardiac studies to the latest research.

The audience of HROJ includes cardiologists, surgeons, physicians, clinicians, surgical investigators, molecular and translational scientists, pharmacologists, epidemiologists, practitioners, educators, nurse, students, and the general community.

The Journal welcomes all types of articles such as original research, review, case-report, mini-review, editorial, short-communication, book-review, opinion, commentary, letter to the Editor, conference proceedings, technical report, errata, illustrations, etc.

We welcome any comments or corrections to improve the quality of our Journal.